Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic syndromes (MDSs) are heterogeneous clonal hematopoietic neoplasms.
• Characterized by ineffective hematopoiesis, peripheral cytopenias, and risk of acute myeloid leukemia (AML) transformation.
• Clinical diversity stems from numerous genetic defects in pathogenesis.

Purpose of the Study:

• To provide an overview of MDS pathogenesis.
• To enhance comprehension of MDS subgroups.
• To examine updated World Health Organization (WHO) and International Consensus Classification (ICC) systems for MDS.

Main Methods:

• Review of recent advances in clinicopathological, immunophenotypic, and molecular landscapes.
• Analysis of evolving classification systems.
• Examination of current and emerging therapeutic approaches.

Main Results:

• Advances reveal a complex genetic basis for MDS heterogeneity.
• Refined classification systems (WHO, ICC) incorporate newer entities.
• Therapeutic strategies are evolving towards personalized medicine targeting core disease mechanisms.

Conclusions:

• Understanding MDS pathogenesis is crucial for classifying and treating these disorders.
• Updated classifications reflect a deeper understanding of MDS heterogeneity.
• Personalized therapies based on genetic profiles promise improved outcomes for MDS patients.